Bi-directional sequencing of NRAS exons 2, 3, and 4 including codons 12, 13, 59, 61, 117, and 146.
NRAS is highly homologous with KRAS; both are members of the most frequently mutated family of oncogenes. NRAS mutations are found in a wide variety of solid tumors, in advanced systemic mastocytosis, and in myeloid neoplasias. Patients with any known KRAS mutation or NRAS mutation may be resistant to certain tyrosine kinase inhibitors. Testing is available separately or in combination with BRAF, HRAS and KRAS in the RAS/RAF Panel.
- Peripheral blood: 5 mL in EDTA tube.
- Bone marrow: 2 mL in EDTA tube.
- FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.